IPDN Q2 2023 Earnings Net Loss of 014 Per Share Reflects Ongoing Investment Phase Supernus Pharmaceuticals SUPN Q1 2026 Earnings EPS Surges Past Expectations but Stock Retreats ATAT Q1 2026 Earnings EPS Surges Past Estimates Stock Declines Despite Strong Beat REAX Q1 2026 Earnings Narrowing Losses with Strong Earnings Beat Centene CNC Q1 2026 Earnings Massive EPS Beat Shocks Estimates Stock Rises 237 CEVA Q1 2026 Earnings EPS Surprises by 122 Amid Strong Licensing Momentum